A Pilot Presurgical Study of Daratumumab (CD38 Antagonist) or JNJ-40346527 in Men With High-Risk Localized Prostate Cancer Followed by Radical Prostatectomy
Phase of Trial: Phase I
Latest Information Update: 21 May 2019
Price : $35 *
At a glance
- Drugs Daratumumab (Primary) ; Edicotinib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- 06 Feb 2019 Planned End Date changed from 1 Jun 2020 to 29 Jun 2020.
- 06 Feb 2019 Planned primary completion date changed from 1 Jun 2020 to 29 Jun 2020.
- 31 Aug 2018 Biomarkers information updated